Nexus Investment Management ULC Has $26.37 Million Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Nexus Investment Management ULC reduced its holdings in Gilead Sciences by 1.6% during Q2, maintaining approximately 3.9% of its portfolio in the biopharmaceutical company, valued at $26.37 million.
• Insider transactions revealed that CEO Daniel O'Day sold 10,000 shares for $1.12 million, while CFO Andrew Dickinson sold 2,500 shares, indicating a slight decrease in their ownership.
• Gilead Sciences received multiple upgrades from analysts, with target prices now ranging from $133.00 to $145.00 as overall sentiment remains positive with a majority rating of "Buy."

Nexus Investment Management ULC cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 237,804 shares of the biopharmaceutical company's stock after selling 3,905 shares during the period. Gilead Sciences comprises approximately 3.9% of Nexus Investment Management ULC's investment portfolio, making the stock its 10th largest holding. Nexus Investment Management ULC's holdings in Gilead Sciences were worth $26,365,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of GILD. Smallwood Wealth Investment Management LLC bought a new position in shares of Gilead Sciences in the first quarter valued at approximately $25,000. Activest Wealth Management boosted its position in Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Goodman Advisory Group LLC bought a new position in Gilead Sciences in the 1st quarter valued at $29,000. Colonial Trust Advisors increased its position in shares of Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 213 shares during the last quarter. Finally, Core Alternative Capital raised its stake in shares of Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 241 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the sale, the chief executive officer owned 591,203 shares of the company's stock, valued at approximately $66,013,726.98. This represents a 1.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the transaction, the chief financial officer directly owned 159,555 shares of the company's stock, valued at approximately $18,120,661.35. The trade was a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 66,000 shares of company stock valued at $7,632,100. 0.27% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on GILD shares. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a research report on Friday, July 25th. Citigroup increased their target price on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a "buy" rating in a research report on Wednesday, October 8th. Rothschild & Co Redburn raised their price target on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a "buy" rating in a research note on Friday, September 12th. Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Finally, JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $135.00 to $145.00 and gave the company an "overweight" rating in a report on Tuesday, September 16th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $118.08.

Gilead Sciences Trading Up 0.2%

NASDAQ:GILD opened at $118.48 on Wednesday. Gilead Sciences, Inc. has a 1 year low of $84.80 and a 1 year high of $121.83. The stock's fifty day moving average price is $114.84 and its two-hundred day moving average price is $110.35. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The company has a market cap of $147.01 billion, a P/E ratio of 23.60, a P/E/G ratio of 0.80 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm's quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the business earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences's dividend payout ratio is presently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.